SCHEMBL18343188

SCHEMBL18343188

CC1(C)OB(c2cccc(NC(=O)CCl)c2)OC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
HTT P42858 6/20 0.47
MITF O75030 4/20 0.47
POLB P06746 2/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
LIPG Q9Y5X9 2/20 0.43
LPL P06858 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
GAA P10253 1/20 0.41
LMNA P02545 3/20 0.41
HIF1A Q16665 2/20 0.41
NOD2 Q9HC29 1/20 0.41
GMPS P49915 1/20 0.40
RAB9A P51151 3/20 0.40
PDGFRB P09619 1/20 0.40
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3264202 0.88 GAA (0.56) ALDH1A1POLBMAPK1CA1CA2
SCHEMBL2357751 0.83 ALDH1A1 (0.54) ALDH1A1HTTPOLBMAPK1NPSR1
SCHEMBL16150246 0.83 HSD17B10 (0.52) ALDH1A1HTTCA1CA2CA9
SCHEMBL29895479 0.83 ALDH1A1 (0.50) ALDH1A1POLBCA1CA2CA9
SCHEMBL561229 0.83 ALDH1A1 (0.50) ALDH1A1POLBCA1CA2CA9
SCHEMBL7139795 0.83 CA1 (0.48) POLBCA1CA2CA9LIPG
SCHEMBL5618327 0.83 CA1 (0.52) ALDH1A1HTTMITFNPSR1CA1
SCHEMBL27332191 0.83 EPHX1 (0.47) ALDH1A1HTTCA1CA2CA9
SCHEMBL1851971 0.82 MAP4K4 (0.43) ALDH1A1HTTCA1CA2CA9
SCHEMBL2236352 0.82 CA1 (0.42) CA1CA2CA9LIPGLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988484-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2021-04-27 US disclosed
US-10988484-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2021-04-27 US disclosed
US-20190315772-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORP LLC (US) 2019-10-17 US disclosed
US-20190315772-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORP LLC (US) 2019-10-17 US disclosed
US-10273248-B2 Glucose uptake inhibitors Kadmon Corportion, LLC (US) 2019-04-30 US disclosed
US-10273248-B2 Glucose uptake inhibitors Kadmon Corportion, LLC (US) 2019-04-30 US disclosed
US-20180298029-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORPORATION LLC (US) 2018-10-18 US disclosed
EP-3313825-A1 GLUCOSE UPTAKE INHIBITORS Kadmon Corporation, LLC (US) 2018-05-02 EP disclosed
WO-2016210330-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORPORATION, LLC (US) 2016-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298029-A1 GLUCOSE UPTAKE INHIBITORS SLC2A1, SLC2A2, SLC2A4 ALDH1A1 539/4885HTT 1172/4885MITF 1493/4885
US-10988484-B2 Glucose uptake inhibitors SLC2A1, SLC2A2, SLC2A4 ALDH1A1 590/4885HTT 954/4885MITF 1497/4885
US-20190315772-A1 GLUCOSE UPTAKE INHIBITORS SLC2A1, SLC2A4, SLC2A2 ALDH1A1 1239/4885HTT 892/4885MITF 1171/4885
US-10273248-B2 Glucose uptake inhibitors SLC2A1, SLC2A2, SLC2A4 ALDH1A1 539/4885HTT 1172/4885MITF 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.